TECENTRIQ® (atezolizumab) 840mg
| Product Overview | |
| Generic Name | TECENTRIQ® (atezolizumab) 840mg |
| Brand Name(s) | Tecentriq |
| Product Type | Originator Brand |
| Form | Single Dose Vial, preservative-free solution for IV infusion |
| Strength | 840mg/14mL |
| Therapeutic Class | PD‑L1 inhibitor immunotherapy |
| ATC Code | L01XC32 |
| Manufacturing & Regulatory | |
| Manufacturer | Hoffmann‑La Roche / Genentech |
| Country | Switzerland (Roche HQ); in USA (Genentech) & global |
| GMP Compliance | FDA/EMA/WHO-GMP |
| COFEPRIS | not assigned a distinct CNIS/Clave |
| Free Sale Certificate | Available from manufacturer/exporter upon request |
| Logistics & Export | |
| MOQ | 5 vials |
| Shelf Life | 24 Months |
| Storage | 2 – 8 °C cold chain |
| Incoterms | EXW, HSN 30049099 |
| Lead Time | 10–21 days |
| Documentation | |
| Certificate of Analysis (COA) | Supplied by Roche/Genentech; distributors also issue COA |
| SDS | Upon Request, not publicly posted |
| CTD Summary | CTD proprietary; available under commercial agreement/license |
Description
Atezolizumab is a PD-L1 immune checkpoint inhibitor used in selected oncology indications including NSCLC, ES-SCLC, unresectable/metastatic HCC, BRAF V600 melanoma in combination therapy, alveolar soft part sarcoma, and ctDNA MRD-positive muscle-invasive bladder cancer after cystectomy. Standard IV adult schedules include 840 mg every 2 weeks, 1,200 mg every 3 weeks, or 1,680 mg every 4 weeks, depending on indication/regimen.
